SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

VERA

Vera Therapeutics
BULLISH
Impact 6/10
Horizonmonths Processed11d 6h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Monitor the pace of TRUTAKNA prescription uptake and payer coverage expansion in coming quarters, as well as the FDA's review of the sBLA for full approval expected in mid-2027. The company's cash runway and ability to manage launch-related SG&A spending will be key to watch.

DirectionBullish
Confidencehigh
Horizonmonths

TRUTAKNA

▲ Bullish Named in this press release
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026
Next catalyst
None dated

What to watchThe FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$29.79
T+0 close · Nov 5, 2026 · via day close
Latest settled
−5.66%
T+5 · $28.10
Vs SPY
−8.25%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $29.79entry
  2. T+1 · 8d ago +2.77%α +0.40% · $30.61
  3. T+5 · 4d ago −5.66%α −8.25% · $28.10
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vera Therapeutics reported Q3 2026 net product revenue of $10.3 million from the initial TRUTAKNA launch following July 7 accelerated FDA approval, with approximately 700 Patient Start Forms received to date. The net loss was $93.7 million ($1.30 per share), wider than the consensus estimate of a $1.62 loss per share, driven by $61.4 million in SG&A expenses for the commercial launch. The company also completed an sBLA submission for full FDA approval, with a decision expected in mid-2027.

Key Financial Metrics

EPS
−$1.30
est −$1.62 · +19.8%
Revenue
$10.3M
est $3.3M · +211.4%
Rating
beat

Key Facts

  • Q3 2026 net product revenue of $10.3 million from TRUTAKNA launch
  • Approximately 700 Patient Start Forms received since July 7 accelerated approval
  • Net loss of $93.7 million ($1.30 per share) vs consensus estimate of $-1.62 per share
  • sBLA submitted for full FDA approval of TRUTAKNA in primary IgAN, decision expected mid-2027
  • Cash, cash equivalents and marketable securities of $384 million as of September 30, 2026; pro forma $459 million after $75 million debt draw in October
  • ORIGIN 3 final efficacy data showed annualized eGFR slope of -0.6 vs -5.6 for placebo (p<0.0001) and 76% risk reduction in composite kidney disease progression

Financial Impact

First product revenue of $10.3 million in Q3 2026, compared to zero in prior year; net loss of $93.7 million vs $80.3 million in Q3 2025; cash position of $384 million plus $75 million drawn in October

revenuenet losscash position

Risk Factors

  • TRUTAKNA is currently approved under accelerated approval; full approval is contingent on confirmatory trial results and FDA review
  • Commercial launch expenses are high ($61.4M SG&A in Q3) and may pressure cash runway despite $459M pro forma cash
  • Competition from other IgAN therapies and potential payer coverage limitations could affect revenue growth

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396989

Track record

25 reports on VERA

Performance horizon

13 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
  5. Nov 5, 202611d ago 8-K Bullish 6/10 No price data
  6. Nov 5, 202611d ago Press Release Bullish 6/10 Viewing Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
  8. Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
  9. Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
  10. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (11h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026